[CAS NO. 1613373-33-3] PCO371
PRODUCTS SPECIFICATIONS [1613373-33-3]
DESCRIPTION [1613373-33-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 635.65 |
| Molecular Formula | C29H32F3N5O6S |
| SMILES | FC(F)(F)OC1=CC=C(C2=NC3(CCN(S(CCC4=C(C)C=C(N5C(NC(C5(C)C)=O)=O)C=C4C)(=O)=O)CC3)C(N2)=O)C=C1 |
Summary
PCO371 is an orally active full agonist of parathyroid hormone receptor 1 (PTHR1) , with no effect on PTH type 2 receptor.
IC50 & Target
PTHR1 [1]
In Vitro
PCO371 is an orally active full agonist of parathyroid hormone receptor 1 (PTHR1), with no effect on PTH type 2 receptor. PCO371 induces cAMP production with an EC 50 of 2.4 μM in COS-7 cells expressing hPTHR1, and 2.5 μM in COS-7 cells transfected with hPTHR1-delNT, and also enhances the phospholipase C activity (EC 50 , 17 μM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02475616 | Chugai Pharmaceutical |
Healthy
|
June 2015 | Phase 1 |
| NCT04209179 | Chugai Pharmaceutical |
Hypoparathyroidism
|
July 23, 2020 | Phase 1 |
| NCT04649216 | Chugai Pharmaceutical |
Healthy Volunteers
|
November 25, 2020 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 196.65 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5732 mL | 7.8660 mL | 15.7319 mL |
| 5 mM | 0.3146 mL | 1.5732 mL | 3.1464 mL |
| 10 mM | 0.1573 mL | 0.7866 mL | 1.5732 mL |